A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity
2020
This work was supported by the NIH grants CA192656 (D.L.D.), FD005113 (D.L.D., A.M.B.), GM135671 (T.G.K.), GM125195 (T.G.K.) and the Tower Cancer Research Foundation grant (A.M.B.). K.R.V. is a CFReT Fellow.
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
10
References
4
Citations
NaN
KQI